Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | CNR2 | P34972 | 2/20 | 0.50 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | CTSS | P25774 | 1/20 | 0.48 |
| ▸ | SIRT2 | Q8IXJ6 | 10/20 | 0.47 |
| ▸ | SIRT1 | Q96EB6 | 6/20 | 0.46 |
| ▸ | SIRT3 | Q9NTG7 | 4/20 | 0.46 |
| ▸ | CTSK | P43235 | 1/20 | 0.45 |
| ▸ | SYK | P43405 | 1/20 | 0.45 |
| ▸ | TLR2 | O60603 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1596691 | 0.91 | CTSL (0.52) | CTSLCTSSSIRT2SIRT1SIRT3 | |
| SCHEMBL13434967 | 0.85 | SIRT2 (0.53) | CTSLCTSSSIRT2SIRT1SIRT3 | |
| SCHEMBL133032 | 0.85 | SIRT2 (0.53) | CTSLCTSSSIRT2SIRT1SIRT3 | |
| SCHEMBL3902571 | 0.85 | SIRT2 (0.53) | CTSLCTSSSIRT2SIRT1SIRT3 | |
| SCHEMBL8054994 | 0.84 | SIRT2 (0.55) | CTSLCTSSSIRT2SIRT1SIRT3 | |
| SCHEMBL3319289 | 0.81 | CTSL (0.56) | CTSLCTSSSIRT2SIRT1CTSK | |
| SCHEMBL1734009 | 0.81 | CTSL (0.56) | CTSLCTSSSIRT2SIRT1CTSK | |
| SCHEMBL4582168 | 0.81 | ANPEP (0.55) | CTSLCTSSSIRT2SIRT1SIRT3 | |
| SCHEMBL4035273 | 0.80 | SIRT2 (0.44) | CTSLCTSSSIRT2SIRT1SIRT3 | |
| SCHEMBL4542544 | 0.79 | SMN1; SMN2 (0.54) | CTSLCTSSSIRT2SIRT1SIRT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1585518-B9 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-08-08 | — | — | EP | disclosed |
| EP-1585518-B1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC (US) | 2012-03-07 | — | — | EP | disclosed |
| EP-1585518-A4 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2009-04-22 | — | — | EP | disclosed |
| US-7166624-B2 | Peptide deformylase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2007-01-23 | — | — | US | disclosed |
| US-20060052423-A1 | Peptide deformylase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2006-03-09 | — | — | US | disclosed |
| EP-1585518-A2 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-10-19 | — | — | EP | disclosed |
| WO-2005032550-A2 | PEPTIDE DEFORMYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052423-A1 | Peptide deformylase inhibitors | PDF, PEPD, DPEP1 | MEN1 2495/4885KMT2A 3860/4885CNR2 4865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.